Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience f

3 hours ago

Stem cell boost (SCB) is effective for managing CAR-T-related hematologic toxicity in relapsed/refractory multiple myeloma (RRMM) patients.
A retrospective multi-institutional study compared SCB (n=39) with supportive care alone (n=52) in patients with prolonged cytopenias post-CAR-T.
SCB led to hematologic recovery in 97.4% of patients, with a median recovery time of 24 days.
By day 90 post-CAR-T, SCB patients had significantly higher hemoglobin (10.6 vs. 8.7 g/dL) and platelet counts (135 vs. 35K/L) compared to non-SCB patients.
Median progression-free survival (PFS) was longer in the SCB group (11.0 months) vs. the non-SCB group (8.2 months).
No new toxicities were attributed to SCB, demonstrating its safety.
The study suggests SCB as a viable strategy for rapid hematologic recovery post-CAR-T therapy.

Hasty Briefsbeta